Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Drug-eluting Stent Implantation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3010 participants.

Also called NCT05955365

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,010 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05955365
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Belgium, France, Germany, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05955365. Randomized; no masking; primary purpose treatment. Start 2023-12-18 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Drug-eluting Stent Implantation
Acronym
MATRIX-2
Condition
Atrial Fibrillation (AF)
Condition
Oral Anticoagulation
Condition
P2Y12 Inhibitor
Intervention (Drug)
P2Y12 inhibitor
Intervention (Drug)
Aspirin
Intervention (Drug)
DOAC
Lead sponsor
Insel Gruppe AG, University Hospital Bern (class: other)
Collaborator
Sahajanand Medical Technologies Limited (class: industry)

Record details

Record id
cardio:ct-nct05955365
Content hash
cf1873d63c2b9ad411f5ed54aed5103f9a1b1d721ee635e43f5ce098c35767ca